Roots Analysis has announced the addition of “Gene Therapy Market (5th Edition), 2022-2035” report to its list of offerings.
Post the emergence of blockbuster gene therapies, such as ZOLGENSMA® (for spinal muscular atrophy type I) and Libmeldy™ (for metachromatic leukodystrophy), this domain has garnered significant interest in the medical community.
To order this 860+ page report, which features 240+ figures and 410+ tables, please visit
https://www.rootsanalysis.com/....reports/view_documen
Like
Comment
Share
